Option chain shows key data for Slam's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Slam.

Slam (OTC:SLAMF) Stock, Option Chain

Slam Corp

Across the recent three months, 8 analysts have shared their insights on Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Zions Bancorp, revealing an average target of $62.75, a high estimate of $67.00, and a low estimate of $59.00. Observing a 10.09% increase, the current average has risen from the previous average price target of $57.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737550834_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zions Bancorp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$61.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Anthony Elian</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$59.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$64.00</td>
<td>-</td>
</tr>
<tr>
<td>David Rochester</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$67.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$61.00</td>
<td>$56.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Zions Bancorp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zions Bancorp compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Zions Bancorp's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Zions Bancorp's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ZION/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zions Bancorp analyst ratings.</a>
<h2>Get to Know Zions Bancorp Better</h2>
Zions Bancorporation is a regional us bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
<h3>Zions Bancorp: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Zions Bancorp showcased positive performance, achieving a revenue growth rate of 3.53% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Zions Bancorp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 25.51%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Zions Bancorp's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.5% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Zions Bancorp's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Zions Bancorp's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ZION

Analyst Expectations For Zions Bancorp's Future

4 analysts have shared their evaluations of Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $6.25, along with a high estimate of $11.00 and a low estimate of $4.00. Highlighting a 41.86% decrease, the current average has fallen from the previous average price target of $10.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1737550815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Century Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$4.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$11.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$5.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Century Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Century Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Century Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Century Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/IPSC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Century Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Century Therapeutics</h2>
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
<h3>Century Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Century Therapeutics displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 434.46%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Century Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3947.66%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Century Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -14.95%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Century Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.76% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.28.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IPSC

4 Analysts Have This To Say About Century Therapeutics

WIIM

ABSI

Absci shares are trading higher after Needham initiated coverage with a Buy rating and a $9 price target.

News

Guidance

SGHC

Super Group shares are trading higher after the company announced that it expects Q4 and FY24 revenue to exceed analyst estimates.

Baird analyst Vikram Kesavabhotla maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $875 to $1200.

Price Target

NFLX

Baird Maintains Outperform on Netflix, Raises Price Target to $1200

Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) shares are trading higher in premarket on Wednesday after the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43123269/p-g-announces-fiscal-year-2025-second-quarter-results" rel="noreferrer noopener">second-quarter earnings results</a>.
The company reported second-quarter sales growth of 2% year-on-year to $21.9 billion, beating the analyst consensus estimate of $21.542 billion.
Organic sales increased 3%, driven by a 2% increase in organic volume and a 1% increase from the favorable geographic mix.
Sales in the Beauty segment remained flat, the Grooming segment gained 1%, and Health Care increased 2%.
Adjusted EPS of $1.88 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beat the consensus estimate of $1.86.</a>
Gross profit increased 1% Y/Y to $11.46 billion. The reported gross margin decreased by 30 basis points to 52.4%.
Operating margin expanded 550 basis points to 26.2%, while operating income for the quarter jumped 30% to $5.7 billion.
P&amp;G held $10.23 billion in cash and equivalents at December-end. Operating cash flow for the quarter was $4.8 billion.
&#8220;The P&amp;G team delivered an acceleration in organic sales growth, core EPS growth and strong cash return to shareowners in the second quarter,&#8221; said Board Chairman, President, and CEO Jon Moeller.
&#8220;Our first-half results keep us on track to deliver within our guidance ranges on all key financial metrics for the fiscal year.&#8221;
Outlook: P&amp;G maintained its guidance range for FY25 organic sales growth of 3%-5% and all-in sales growth of 2%-4%. P&amp;G maintained its FY25 EPS growth outlook of 10%-12% versus an EPS of $6.02 in FY24.
P&amp;G reiterated its adjusted EPS outlook of $6.91 &#8211; $7.05 versus the $6.93 estimate. P&amp;G continues to expect a commodity cost headwind of approximately <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$200 million after tax for fiscal 2025.</a>
P&amp;G expects unfavorable foreign exchange rates will be a headwind of approximately $300 million after tax.
P&amp;G continues to expect adjusted free cash flow productivity of&nbsp;90%&nbsp;and expects to pay around&nbsp;$10 billion&nbsp;in dividends and repurchase&nbsp;$6&nbsp;billion&nbsp;to&nbsp;$7 billion&nbsp;of common shares in fiscal 2025.
Price Action: PG shares are trading higher by 3.44% at $167.29 in premarket at the last check Wednesday. 
Photo via Shutterstock.

Earnings

Equities

Dividends

Buybacks

Movers

General

Gillette Parent Procter & Gamble Q2 Earnings: Navigates Commodity And Forex Challenges, Maintains Core FY25 Outlook

Australian uranium producer Paladin Energy (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PALAF#OTC">PALAF</a>) soared following President Trump's announcement of a $500 billion <a target="_blank" href="https://www.benzinga.com/25/01/43111153/nvidia-and-ai-stock-rises-as-trump-announces-500-billion-stargate-ai-infrastructure-venture" rel="noreferrer noopener">"Stargate AI" initiative</a>. As investments pour into AI infrastructure, <a target="_blank" href="https://www.benzinga.com/topic/nuclear-power" rel="noreferrer noopener">nuclear power</a> emerged as the best solution for a stable, low-carbon energy supply.
In 2024, Paladin strategically strengthened its position in the global uranium market with its milestone acquisition of Fission Energy, taking over the high-profile Patterson Lake South (PLS) project in Canada's Athabasca Basin.
"This acquisition is transformative," <a target="_blank" href="https://www.paladinenergy.com.au/wp-content/uploads/2025/01/61247717.pdf" rel="noreferrer noopener">said</a> CEO Ian Purdy. "The PLS project elevates Paladin to a new scale, cementing our status as one of the world's top uranium companies." The PLS project, known for its high-grade uranium deposits, significantly boosts Paladin's portfolio with an estimated resource of over 130 million pounds of uranium oxide equivalent.
The acquisition, finalized on December 24, met stringent Canadian government conditions to ensure national security and counter foreign influence. Among these conditions is the <a target="_blank" href="https://www.benzinga.com/markets/commodities/24/03/37513662/the-answer-cannot-be-china-canadas-wilkinson-says-mining-scrutiny-intensifies-as-srg-scraps-d" rel="noreferrer noopener">prohibition of China-sourced financing</a> for the project and the restriction of uranium sales to China beyond existing agreements with China General Nuclear Power Group.
Outside of winter drilling programs for resource expansion at PLS and neighboring prospects, the firm is preparing the next exploration phase at the Michelin Project in Newfoundland and Labrador.
With six confirmed deposits in the area, containing over 80 million pounds of Measured and Indicated resources, Paladin is optimistic about further growth.
Meanwhile, Paladin's Langer Heinrich mine in Namibia continues to grow its production. The mine produced 639,000 pounds of uranium oxide in the December quarter, including a record 308,000 pounds in December alone. By mid-2025, the mine will transition from processing stockpiled ore to high-grade ore, boosting annual production to the guidance range of 3 to 3.6 million pounds of uranium oxide.
"Restarting a mine and large processing facility involves a lot of moving parts. I am extremely happy with the work my team has done," noted COO Paul Hemburrow.
The Paladin's growing portfolio of over 544 million pounds of uranium oxide resources positions it as one of the most compelling pure-play uranium investments. With a diversified asset base and a dual listing in Australia and on the Toronto Stock Exchange (under the ticker PDN), the company is positioned to capitalize on the growing demand for nuclear energy.
Price Watch: Paladin Energy closed the Australian trading session at AU$9.19, up 10.06% for the day.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/01/43093586/barrick-looks-into-portfolio-optimization-sees-pakistan-as-the-new-frontier" target="_blank" rel="noreferrer noopener">Barrick Looks Into Portfolio Optimization, Sees Pakistan As ‘The New Frontier'</a></li>
</ul>
Nuclear Power Plant Image via Shutterstock

Commodities

Legal

Markets

Media

PALAF

Paladin Energy Soars On Corporate Achievements, Trump's Appetite For AI

WestPark Capital analyst Casey Ryan maintains Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) with a Buy and raises the price target from $1.3 to $2.

MVIS

WestPark Capital Maintains Buy on Microvision, Raises Price Target to $2

Commercial NdPr Metal Production Begins at Independence, MP's Fully Integrated Rare Earth Magnet Manufacturing Facility in Texas for the First Time in a Generation
Trial Production of Automotive-Grade, Sintered NdFeB Magnets Underway, with First Deliveries on Track for Year-End
MP Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) has reached a pivotal milestone in restoring the U.S. rare earth magnet supply chain. The company's flagship Independence facility in Fort Worth, Texas, has commenced commercial production of neodymium-praseodymium (NdPr) metal and trial production of automotive-grade, sintered neodymium-iron-boron (NdFeB) magnets. These achievements bring the U.S. closer to reestablishing a fully integrated, domestic supply chain for these critical components for the first time in decades.

MP Materials Announces Start Of NdPr Metal Production At Texas Facility; Trial Production Of Automotive-Grade NdFeB Magnets Underway; First Deliveries Expected By Year-End

WKSP

Worksport's Terravis Energy Unveils AI-Enhanced Heat Pump Revolutionizing Home Climate Control; Says 20-Day Countdown To Global Reveal Begins

Textron shares are trading lower after the company missed Q4 revenue expectations and issued FY25 EPS guidance below estimates.

Seagate Technology shares are trading higher after the company reported Q2 EPS and revenues above analyst estimates.

Deutsche Bank analyst Brian Bedell reiterates State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Hold and lowers the price target from $104 to $103.

Reiteration

Deutsche Bank Reiterates Hold on State Street, Lowers Price Target to $103

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Cocrystal Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) with a Buy and maintains $7 price target.

COCP

HC Wainwright & Co. Reiterates Buy on Cocrystal Pharma, Maintains $7 Price Target

Citigroup analyst Asiya Merchant maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $120 to $125.

Citigroup Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $125

Deutsche Bank analyst David Begleiter maintains H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) with a Buy and lowers the price target from $75 to $72.

Deutsche Bank Maintains Buy on H.B. Fuller, Lowers Price Target to $72

Citigroup analyst Andrew Kaplowitz maintains 3M (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) with a Neutral and raises the price target from $142 to $152.

Citigroup Maintains Neutral on 3M, Raises Price Target to $152

Industry partners to provide funding and data to support ACAT&#x2122; model improvements
Simulations Plus, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLP#NASDAQ">SLP</a>) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform.
The collaboration focuses on enhancing the predictive capabilities of the GastroPlus advanced compartmental absorption and transit (ACAT&#x2122;) model to support the development of immediate release (IR) oral drug products. Using data gathered from public sources and members of the ETC, physiologically based pharmacokinetics (PBPK) and biopharmaceutics modeling (PBBM) experts and software engineers at Simulations Plus will look to complete key objectives as defined by the partnership. These advancements, including implementation of novel product-particle size distribution (P-PSD) methodologies and enhanced food effect modeling features, will provide researchers with powerful tools to improve drug product development, reduce reliance on animal studies, and streamline regulatory submissions.

Comments

Slam

Slam (SLAMF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga